host
plasma
membran
protein
incorpor
bud
retroviru
particl
block
subsequ
entri
suscept
target
cell
three
accessori
protein
encod
divers
retrovirus
nef
eiav
mlv
glycogag
independ
disrupt
antivir
activ
redirect
site
virion
assembl
plasma
membran
intern
endosom
compart
pseudotyp
retrovirus
particular
glycoprotein
eg
vesicular
stomat
glycoprotein
vsv
g
render
infect
particl
resist
inhibit
virionassoci
better
understand
viral
determin
effect
assess
use
mlv
mpmv
virion
core
pseudotyp
glycoprotein
arenaviru
coronaviru
filoviru
rhabdoviru
paramyxoviru
orthomyxoviru
genera
infect
particl
pseudotyp
amphotropicmlv
influenza
viru
glycoprotein
decreas
whether
core
provid
mlv
mpmv
particl
gener
three
core
pseudotyp
glycoprotein
either
avian
leukosi
virusa
human
endogen
retroviru
k
hervk
ecotropicmlv
measl
morbilliviru
lymphocyt
choriomening
mammarenaviru
lcmv
marburg
viru
ebola
viru
sever
acut
respiratori
syndromerel
coronaviru
sarscov
vsv
insensit
contrast
particl
pseudotyp
mpmv
rabi
viru
rabv
glycoprotein
sensit
particular
retrovir
core
resist
particular
glycoprotein
correl
reduc
incorpor
particl
rout
viral
entri
find
indic
nonretrovirus
may
sensit
addit
viral
glycoprotein
retrovir
core
influenc
sensit
import
inhibit
retrovirus
underscor
converg
evolut
among
three
nonmonophylet
retrovirus
encod
structur
unrel
inhibitor
one
retrovirus
caus
tumor
mice
second
anemia
hors
third
caus
aid
incorpor
retroviru
particl
block
entri
target
cell
via
mechan
depend
viral
glycoprotein
demonstr
retrovirus
pseudotyp
glycoprotein
sever
nonretrovirus
also
inhibit
suggest
envelop
virus
retrovirus
may
also
inhibit
addit
found
sensit
determin
retroviru
core
well
glycoprotein
better
understand
inhibit
virus
hope
extend
fundament
understand
viru
replic
nativ
role
cell
perhap
advanc
develop
new
antivir
strategi
nef
import
maxim
replic
vivo
progress
aid
nef
multifunct
accessori
protein
downregul
mhc
tcr
cell
surfac
nef
also
enhanc
infect
singleround
infect
experi
overcom
antivir
effect
though
two
potent
restrict
factor
incorpor
bud
virion
inhibit
subsequ
fusion
virion
membran
target
cell
membran
nef
counteract
remov
cell
surfac
incorpor
nascent
virion
viru
inhibit
siv
lack
nef
also
inhibit
siv
nef
counteract
inhibit
potenc
proport
preval
siv
wild
primat
popul
two
exampl
converg
evolut
antiserinc
function
viral
encod
protein
found
outsid
primat
immunodefici
virus
murin
leukemia
viru
mlv
glycogag
equin
infecti
anemia
viru
eiav
viral
antagonist
activ
neither
share
sequenc
structur
homolog
nef
mechan
virionassoci
inhibit
entri
unknown
block
manifest
virion
attach
target
cell
appar
stage
fusion
pore
expans
virion
content
mix
target
cell
cytoplasm
virion
core
transfer
cytoplasm
inhibit
otherwis
isogen
virion
pseudotyp
env
glycoprotein
differ
isol
exhibit
rang
depend
nef
sensit
increas
sensit
antibodi
peptid
target
membraneproxim
extern
region
suggest
somehow
alter
conform
glycoprotein
near
virion
membran
importantli
particl
pseudotyp
vesicular
stomat
viru
vsv
g
ebola
viru
glycoprotein
resist
antivir
activ
initi
observ
suggest
correl
locat
viral
fusion
sensit
activ
glycoprotein
mediat
fusion
cell
surfac
env
amphotrop
mlv
amlv
sensit
mediat
fusion
endolysosom
compart
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
vsvg
ebola
gp
resist
taken
togeth
result
indic
virion
glycoprotein
viral
determin
sensit
multipass
transmembran
local
almost
exclus
plasma
membran
absenc
countermeasur
envelop
virus
would
expect
encount
viral
egress
potenti
subject
antivir
effect
sought
address
breadth
antivir
activ
assess
whether
rout
entri
impact
sensit
viral
glycoprotein
antivir
effect
investig
whether
coexpress
viral
product
could
inhibit
varieti
glycoprotein
pseudotyp
hiv
mlv
mpmv
core
use
system
test
sensit
number
retrovir
env
well
repres
glycoprotein
arenaviru
coronaviru
filoviru
rhabdoviru
paramyxoviru
orthomyxoviru
genera
consist
previou
find
observ
glycoprotein
major
determin
sensit
mani
glycoprotein
univers
insensit
antivir
effect
glycoprotein
amlv
influenza
inhibit
viral
core
pseudotyp
test
correl
observ
sensit
rout
viral
entri
mediat
viral
glycoprotein
unexpectedli
also
observ
sensit
antivir
activ
mpmv
rabi
viru
rabv
glycoprotein
depend
retrovir
core
onto
pseudotyp
find
reveal
interplay
virion
core
glycoprotein
determin
sensit
antivir
activ
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
determin
viral
glycoprotein
sensit
antivir
activ
assess
infect
pseudotyp
gfpexpress
lentivir
vector
produc
presenc
absenc
includ
panel
divers
select
retrovir
env
glycoprotein
includ
human
immunodefici
avian
leukosi
similar
find
other
observ
caus
greater
reduct
viral
infect
amlv
pseudotyp
signific
reduct
observ
ebov
vsv
pseudotyp
fig
tabl
interestingli
observ
reduct
infect
influenza
rabv
pseudotyp
pseudotyp
display
reduc
infect
observ
indic
restrict
dictat
viral
glycoprotein
mediat
fusion
fusion
mediat
influenza
rabv
occur
phdepend
fashion
endolysosom
compart
amlv
mpmvand
fusion
occur
phindepend
manner
next
test
panel
filovir
glycoprotein
sensit
restrict
glycoprotein
requir
proteolyt
process
follow
intern
target
cell
util
lysosom
protein
initi
viral
fusion
addit
ebov
marv
glycoprotein
test
fig
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
shown
fig
none
filovir
glycoprotein
inhibit
presenc
howev
may
modest
differ
sensit
activ
specif
restv
tafv
gp
appear
slightli
sensit
respect
inhibit
compar
either
mayinga
makona
ebola
viru
glycoprotein
respect
nef
mlv
glygogag
eiav
counteract
antivir
activ
remov
protein
cell
surfac
reloc
endosom
compart
abil
viral
glycoprotein
reloc
normal
plasma
membran
local
antivir
protein
previous
shown
env
human
thu
reason
viral
glycoprotein
may
confer
resist
activ
reloc
intern
membran
compart
test
compar
incorpor
viruslik
particl
vlp
pseudotyp
variou
glycoprotein
shown
fig
found
vlp
univers
incorpor
irrespect
viral
glycoprotein
present
figur
replic
blot
hervk
env
show
consist
lower
level
incorpor
viral
particl
data
shown
howev
observ
like
caus
pleiotrop
effect
cell
transfect
glycoprotein
cell
growth
significantli
reduc
compar
transfect
reduc
level
gag
gfp
also
observ
fig
data
shown
regardless
direct
correl
exclus
virion
resist
antivir
effect
evid
previou
report
indic
mlv
virion
pseudotyp
env
suscept
antivir
effect
howev
presenc
observ
modest
reduct
viral
titer
pseudotyp
virion
fig
respons
discrep
sought
determin
viral
core
modul
suscept
antivir
activ
thu
test
panel
glycoprotein
sensit
pseudotyp
differ
virion
core
first
test
sensit
panel
glycoprotein
fig
mlv
viral
core
figur
tabl
observ
glycoprotein
sensit
restrict
core
amlv
flu
rabi
also
restrict
pseudotyp
mlv
core
addit
observ
mpmv
env
sensit
serinc
restrict
pseudotyp
onto
mlv
core
wherea
pseudotyp
onto
core
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
return
initi
impetu
explor
differ
core
observ
reduct
infect
pseudotyp
mlv
core
produc
presenc
similar
magnitud
inhibitori
effect
report
ahi
et
al
due
observ
differ
sensit
mpmv
pseudotyp
mlv
core
next
test
antivir
activ
panel
glycoprotein
pseudotyp
onto
mpmv
core
figur
tabl
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
discuss
initi
report
indic
viral
glycoprotein
determin
sensit
antivir
activ
suggest
viral
glycoprotein
mediat
fusion
via
phdepend
endocyt
entri
pathway
resist
antivir
activ
examin
issu
pseudotyp
use
glycoprotein
divers
famili
envelop
virus
assess
sensit
restrict
observ
restrict
virion
pseudotyp
glycoprotein
sever
retrovirus
amlv
mpmv
influenza
orthomyxovirida
rabi
rhabdovirida
knowledg
first
time
antivir
activ
describ
nonretrovir
glycoprotein
glycoprotein
virus
studi
retrovir
pseudotyp
remain
establish
infect
authent
influenza
rabi
virus
affect
serinc
famili
member
addit
observ
influenza
rabi
glycoprotein
demonstr
mediat
entri
via
endocyt
rout
protect
antivir
effect
env
glycoprotein
retrovirus
mlv
previous
found
inhibit
report
mpmv
glycoprotein
well
interestingli
saw
reduct
infect
autolog
pseudotyp
mpmv
core
produc
presenc
observ
unexpect
given
lentiand
gammaretrovirus
encod
accessori
factor
counteract
activ
yet
function
intact
mpmv
viral
gene
known
miss
gfpexpress
mpmv
vector
env
complement
tran
transfect
sensit
antivir
effect
human
surprisingli
observ
particular
glycoprotein
display
differ
sensit
antivir
effect
depend
viral
core
onto
pseudotyp
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
core
pseudotyp
env
inhibit
observ
pseudotyp
mlv
hiv
core
respect
previou
report
demonstr
similar
magnitud
inhibit
mlv
endogen
serinc
activ
regardless
show
littl
sensit
pseudotyp
onto
core
neutral
monoclon
antibodi
target
membraneproxim
domain
glycoprotein
alter
presenc
given
membran
proxim
domain
gag
make
contact
retrovir
tm
one
imagin
potenti
influenc
interact
tm
virion
essenti
infect
similar
fashion
might
influenc
retrovir
core
interact
heterolog
glycoprotein
test
restrict
activ
coredepend
ie
rabi
viru
mpmv
glycoprotein
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
plasmid
dna
plasmid
use
studi
describ
tabl
includ
addgen
nih
aid
reagent
program
code
number
applic
full
plasmid
sequenc
obtain
base
vector
bear
codonoptim
env
cytoplasm
tail
truncat
residu
residu
similar
previous
describ
gener
use
standard
clone
techniqu
avail
addgen
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
